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Abstract 
MTA3 functions as a transcriptional repressor 
through interacting with histone deacetylases and 
nucleosome remodelling complexes such as Mi-
2/NuRD.  
Since MTA3 inhibits expression of SNAIL, a 
transcriptional repressor of the cell adhesion protein 
E-cadherin, downregulation of MTA3 was found to 
be associated with reduced E-cadherin levels and 
advanced cancer stages. Recent data also revealed 
upregulation of MTA3 in non-small lung cancer 
cells and highly aggressive subtypes of endometrial 
cancer, additionally indicating cancer-promoting 
effects of MTA3. 
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Identity 
Other names: KIAA1266 
HGNC (Hugo): MTA3 
Location: 2p21 
DNA/RNA 
Description 
The human MTA3 gene was identified through 
sequence homologies to other members of the MTA 
gene family (human MTA1, human MTA2, murine 
MTA3).  
The human MTA3 gene is composed of 14 exons. 
The MTA3 promoter sequence contains SP1, AP1, 
and oestrogen receptor binding sites (ER half sites). 
 
Genomic organization of the human MTA3 gene. The intron/exon structure of MTA3 with start (ATG) and stop (TAA) codons 
indicated. All 14 exons are depicted; the intron sequences shortened for better graphical visualization. 
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Domain structure of the MTA3 protein. BAH (bromo-adjacent homology) domain: putative protein-protein interaction domain, 
involved in gene silencing; ELM (Egl-27 and MTA1 homology) domain: unknown function; SANT (SWI3, ADA2, N-CoR and 
TFIIIB B) domain: putative DNA binding domain; ZnF (GATA-type zinc finger) domain: direct DNA binding domain. 
 
Transcription 
Two open reading frames of 1785 bp (isoform 1; 
594 aa; MTA3L) and 1548 bp (isoform 2; 515 aa; 
MTA3S, MTA3) were identified and predicted to 
be transcribed. The smaller isoform (MTA3S = 
MTA3) appears to be the most abundantly 
expressed isoform at the RNA and protein level. 
Pseudogene 
PGO.9606.51655; PGO.9606.72237. 
Protein 
Description 
MTA3 functions as a transcriptional repressor by 
interacting with histone deacetylases and 
nucleosome remodelling complexes such as Mi-
2/NuRD. 
Expression 
MTA3 expression has been found in normal human 
breast, ovarian, lung, and endometrial epithelial 
cells, in malignant breast, ovarian, lung, and  
endometrial cancer cells and cancer cell lines, in 
trophoblast cells and chorionic cancer cell lines, in 
germinal centre B cells, and in B cell-derived 
lymphomas.  
A tissue distribution analysis of MTA3 expression 
in mice revealed a widespread distribution of 
MTA3 in the developing embryo and in adult 
tissues (heart, brain, spleen, lung, liver and kidney). 
Localisation 
MTA3 exhibits primarily a nuclear localisation, 
although additional cytoplasmic localisation has 
been described. 
Function 
In epithelial cells, MTA3 maintains the expression 
of E-cadherin through the suppression of the E-
cadherin inhibitor SNAIL.  
Expression of MTA3 is regulated by oestrogens via 
direct binding of the oestrogen receptor to the 
MTA3 promoter and is thus involved in the 
generation and maintenance of oestrogen-dependent 
epithelia such as the breast ductal epithelium. 
 
 
The MTA3 regulation network. A. Breast ductal epithelia cells; epithelial cancer cells. B. Germinal center B lymphocytes; B 
cell-derived lymphomas. The regulation of MTA3 expression and its target genes by transcriptional activators (green) and 
transcriptional repressors (red) is shown. ER: oestrogen receptor. 
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Mammary gland development 
Animal experiments revealed involvement of 
MTA3 expression in mammary gland 
morphogenesis mediated by the suppression of the 
Wnt4 signalling pathway and upregulation of 
epithelial cell adhesion proteins such as E-cadherin. 
Normal mammary gland development, as 
confirmed and studied by several knock out and 
knock in mouse models, relies on the concerted and 
correct integration of divers signalling pathways, 
including the Wnt signalling pathway. Secretion of 
Wnt factors and their binding by mammary 
epithelial cells is necessary for correct gland 
development and its deregulation has been 
described to be involved in tumorigenesis. MTA3 
has been shown to inhibit Wnt4 expression by its 
transcriptional repression function, causing reduced 
Wnt4 secretion and subsequent lower beta-catenin 
levels. Therefore, based on the observations made 
with transgenic mouse models, expression of 
MTA3 in mammary epithelial cells has been 
associated with the inhibition of ductal branching in 
virgin and pregnant murine mammary glands. 
Epithelial cancer 
Reduced MTA3 expression in epithelial breast 
cancer, endometrial cancer, and ovarian cancer is 
associated with cancer progression by promoting 
the epithelial-mesenchymal transition (EMT). It is 
principally believed that reduced expression of 
MTA3 allows higher expression levels of SNAIL 
and SLUG, two repressors of metastasis-associated 
cell adhesion proteins such as E-cadherin and 
occludin. Conversely, MTA3 expression was found 
to be elevated in non-small lung cancer and in 
uterine non-endometrioid cancer, in which a 
growth-promoting effect of MTA3 overexpression 
was suggested. 
Haemangiogenesis and lymphomagenesis 
A high expression level of MTA3 was found in 
germinal centre B lymphocytes, suggesting an 
involvement in B cell maturation by direct 
interaction with BCL6. BCL6 (B-cell lymphoma-6) 
is a transcriptional repressor that is co-expressed 
with MTA3 in the germinal centre, where normal B 
cells proliferate and undergo maturation. BCL6 
functions as a transcriptional repressor and 
suppresses, in cooperation with MTA3, the 
expression of PRDM1 (Pr domain-containing 
protein 1), a master regulator of plasma cell 
differentiation. Overexpression of BCL6 is often 
observed in lymphomas, especially in large B-cell 
lymphomas. Thus, the cooperative action of BCL6 
together with MTA3 is believed to block 
differentiation of large B-cell lymphomas, 
facilitating lymphomagenesis. 
Placenta development 
A conspicuously high expression level of MTA3 in 
trophoblast cells and trophoblast tumour cells has  
suggested involvement of MTA3 in placenta 
development and homeostasis. MTA3 expression 
was found to be elevated in preeclampsia patients 
and to negatively interfere with hCG (human 
chorionic gonadotropin) expression. 
Homology 
MTA3 exhibits a high homology to human MTA1, 
MTA2, and murine MTA3. 
Implicated in 
Endometrial cancer 
Note 
MTA3 expression is significantly reduced in 
endometrioid adenocarcinomas of poor 
differentiation, although not associated with 
patients' survival.  
By contrast, in uterine non-endometrioid 
carcinomas, a highly aggressive subtype of 
endometrial cancer, MTA3 expression 
demonstrated a significant association with FIGO 
surgical stage, lymph node involvement, and 
lymphovascular space invasion.  
In uterine non-endometroid cancer, MTA3 was also 
revealed to be a significant independent prognostic 
parameter, associated with patients' progression-
free survival, cause-specific survival, and overall 
survival. 
Ovarian cancer 
Note 
MTA3 expression is reduced in ovarian cancer with 
poor differentiation, although not at significant 
levels. 
Breast cancer 
Note 
Although extensively studied on breast cancer cells 
and tissues, revealing a close correlation of MTA3 
expression with oestrogen receptor expression, no 
studies have yet shown a direct association of 
MTA3 expression with clinicopathological 
parameters in breast cancer. 
Lung cancer 
Note 
MTA3 was found to be upregulated in NSCLC 
(non-small cell lung cancer) tissues and its 
overexpression correlated with lymph node status 
and poor patients' prognosis. 
Gastric cancer, oesophagal cancer 
Note 
In gastroesophageal junction (GEJ) 
adenocarcinomas, MTA3 expression was found to 
be reduced in cancer tissues and reduced MTA3 
expression correlated with worse overall patients' 
survival. 
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Ovary (non-malignant) 
Note 
Murine ovarian granulosa cells of all follicular 
stages were shown to express high levels of MTA3. 
Expression of MTA3 in granulosa cells was also 
shown to promote cell cycle progression by 
controlling entry into the M phase. 
Placenta 
Note 
A high expression level of MTA3 was observed in 
placental trophoblast cells and chorionic carcinoma 
cells.  
In patients with preeclamptic gestational disease, 
MTA3 expression was found to be downregulated 
and shown to be involved in human chorionic 
gonadotropin expression by directly repressing the 
hCG promoter, leading to dysregulated hCG 
expression as observed in preeclampsia. 
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